1 - 5 toradh á dtaispeáint as 5 toradh san iomlán ar an gcuardach 'Ana Oaknin (14956029)', am iarratais: 0.01s Beachtaigh na torthaí
  1. 1
    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... de réir Stephanie Lheureux (16797697)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... de réir Stephanie Lheureux (16797697)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... de réir Stephanie Lheureux (16797697)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... de réir Stephanie Lheureux (16797697)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... de réir Stephanie Lheureux (16797697)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: